FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

ALSO NOTED: Myogen's ambrisentan gets fast tracked; Eli Lilly initiates Phase III trial; and much more...

Tools

> The FDA has granted fast track designation to ambrisentan, Myogen's pulmonary arterial hypertension drug. Release

> Eli Lilly has initiated a Phase III study of Enzastaurin, a possible treatment for relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer. Release

> Generic drugmaker American Pharmaceutical Partners has received two tentative approvals from the FDA for Ondansetron Injection, USP, single-dose and multiple-dose vials, the generic equivalent of GSK's Zofran. The injection treats nausea and vomiting associated with cancer chemotherapy. Release

> The FDA has given the go-ahead for Kamada to initiate Phase III trials for API, lung disease treatment. Report

And Finally... If you drink three or more cups of coffee, you might want to put the coffee cup down and step away from the pot. Researchers have found that coffee increases the risk of heart attack in those who metabolize caffeine slowly. Article


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about Phase III   Eli Lilly   GlaxoSmithKline   brain cancer   Myogen   pulmonary arterial hypertension   hypertension   Fast Track designation